E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To investigate the pharmacodynamics of PSN9301 in patients with type 2 diabetes in relation to dosing regimen. |
|
E.2.2 | Secondary objectives of the trial |
1) To assess the safety and tolerability 2) To investigate the dose linearity (dose proportionality) and PK of the ascending doses. |
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
1. Patients must give their signed informed consent before any trial related activities. Trial related activities are any procedures that would not have been performed during the normal management of the patient.
2. Patients diagnosed with type 2 diabetes according to WHO criteria.
3. Diabetes treatment: Diet treatment only for at least 2 weeks prior to screening, or ongoing treatment with oral antidiabetics, which must be withdrawn for a minimum of 2 weeks before dosing.
4. Males aged 30 <= age <= 74 years, or females aged 30 <= age <= 74 years if hysterectomised and therefore of no childbearing potential, or females aged 55 <= age <= 74 years of no childbearing potential as defined by amenorrhoea at least for the 12 months prior to inclusion.
5. Body mass index (BMI) between 22 and 35 kg/m2 inclusive.
6. 7.5 <= HbA1C <= 10.0%7. Plasma C-peptide within the normal reference range
8. Fasting blood glucose (FBG) 7.2 mmol/L <= FBG <= 12.0 mmol/L measured in plasma |
|
E.4 | Principal exclusion criteria |
1. Pharmacological treatment with any of the following: Systemic steroids (within the last month), beta-blockers, and hormones (within the last month, hormone replacement therapy by female patients excluded).
2. Any medication that the Investigator expects could interfere with blood glucose levels.
3. Diabetic side complications
4. History of severe pancreatitis interfering with blood glucose levels (as evaluated by the Investigator).
5. History of, or current impaired hepatic function, ALAT or alkaline phosphatase >= 2 times upper normal level, and clinically increased liver size.
6. Creatinine clearance (calculated according to the Cockcroft-Gault formula), that in the opinion of the investigaor does indicate renal impairment: Creatinine clearance (mL×min-1) = (140 – age) × body weight (kg) (× 0.85 for females) / 72 × serum creatinine (mg/dL)
7. Hypertension (whether treated or not): systolic blood pressure > 160 mmHg blood pressure and/or >= 99 mmHg for diastolic blood pressure in the supine position.
8. History of, or current cardiac problems, as angina pectoris, myocardial infarction, or symptoms of ischemic heart disease.
9. Supine heart rate higher than 90 beats/min at each of 2 consecutive evaluations.
10. Clinically significant abnormal 12-lead ECG (as evaluated by the Investigator).
11. Positive urine pregnancy test (for female patients only).
12. Any disease or condition which the Investigator feels will interfere with the trial.
13. Patients who are known to have serum hepatitis or who are carriers of the Hepatitis B surface antigen (HBsAg) or Hepatitis C antibodies, or have a positive result to the test for HIV antibodies.
14. Patients with acute gastrointestinal symptoms at the time of entering the trial (e.g. nausea, vomiting, diarrhoea, or heartburn).
15. Any clinically significant abnormal laboratory test results at screening.
16. Patients who have received an investigational drug (new chemical entity or licensed product) in the month preceding the start of dosing, except antidiabetic medication.
17. Patients who have a significant history of alcoholism or drug/chemical abuse, or who have a positive result in the urine drug/alcohol screen, or who consume more than 21 units of alcohol per week (one unit of alcohol equals about 250 mL of beer or lager, one glass of wine, or 20 mL spirits).
18. Patients with a significant use of caffeine containing beverages (greater than 8 cups per day).
19. Patients who smoke more than 10 cigarettes, or the equivalent, per day and is unable to refrain from smoking during 3 days prior to the first dosing day and during the confinement period.
20. Patients with mental incapacity or language barriers which preclude adequate understanding or co-operation, who are unwilling to participate in the study, or who in the opinion of their general practitioner or the Investigator should not participate in the study.
21. Patients who have taken part in strenuous exercise within 4 days prior to dosing in this trial. Whether strenuous exercise has been undertaken will be evaluated by the Investigator, and strenuous exercise is not allowed during the trial.
22. Fasting blood glucose > 15 mmol/L more than 3 times during a 48-hour period during the period from screening to the run-in phase as measured in plasma. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Pharmacodynamic endpoints: DP IV, insulin, glucose (including OGTT results), food intake (% meal consumption) and satiety. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 11 |
E.8.9.1 | In the Member State concerned days | |